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ABSTRACT
The histone methyltransferase EZH2 plays a role in maintenance of the stem 
component of cancer, and its overexpression and/or mutation typically drives tumor 
aggressiveness, drug resistance and patients’ poor prognosis. In this study, we use 
mouse and human medulloblastoma stem-like cells belonging to the Sonic Hedgehog 
subgroup (SHH MB-SLCs) and demonstrate that genetic suppression of EZH2 reduces 
the level of its histone mark H3K27me3 and lowers proliferation and self-renewal. We 
designed an EZH2 inhibitor (EZH2i) as a simplified analog of EPZ005687 and GSK2816126, 
MC3629, and we tested its biological activity in SHH MB-SLCs. Pharmacological inhibition 
of EZH2 impairs SHH MB cells proliferation and self-renewal, and induces apoptosis in 
vitro. Finally, we generated xenograft MB-SLCs orthotopic tumors in nude mice to test 
MC3629 in vivo. In treated mice, we observed impairment of tumor growth, together 
with induction of apoptosis and reduction of proliferation and stemness.
Overall, these findings describe EZH2 as a druggable target in MB and provide 
insight into the biological activity of MC3629 as an EZH2i.
INTRODUCTION
The histone methyltransferase (HMT) Enhancer 
of Zeste Homolog 2 (EZH2) is the catalytic subunit of 
the polycomb repressive complex 2 (PRC2) [1], which 
is responsible for methylation of histone H3 on lysine 
27 up to its trimethylated form (H3K27me3) on the 
promoter region of target genes. EZH2/PRC2 induces an 
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epigenetic change that regulates transcriptional silencing 
[2–4] and plays a pivotal role in different biological 
processes including differentiation, maintenance of cell 
identity and proliferation [5]. EZH2 overexpression 
and mutations occur in several malignancies [6] and are 
usually associated with aggressive tumors, drug resistance 
and poor prognosis [7–9].
As far as brain cancers, EZH2 expression increases 
with tumor grade in adult and pediatric tumors and it is 
a poor prognostic factor [10]. Medulloblastoma (MB) is 
the most common malignant pediatric brain tumor [11] 
and is among those tumors that overexpress EZH2 [12, 
13]. EZH2 genetic or pharmacological targeting has been 
shown to impair MB cells growth [12].
Interestingly, EZH2 is known to sustain self-
renewal of cancer stem-like cells (SLCs) [14, 15]. In 
the hierarchical organization of tumor-cell populations 
envisioned by the cancer stem cell hypothesis, initiation, 
maintenance, and advancement of tumor growth are 
considered mainly properties of the SLCs compartment. 
Thus, EZH2-targeting drugs have become attractive 
weapons in cancer therapy [16] and research effort 
on developing enzymatic inhibitors is fueled [17]. 
Nevertheless, in vivo use of 3-deazaneplanocin A (DZNep) 
[18], a S-adenosyl-L-homocysteine (SAH) hydrolase 
inhibitor strongly effective against EZH2 in vitro, has 
been stopped because of toxicity in mice [19], and some 
catalytic S-adenosyl-L-methionine (SAM)-competitive 
EZH2 inhibitors (EZH2i) available for clinical use at 
the beginning of our study, such as EPZ005687 [20] and 
GSK2816126 [21], have a limitation for their use due to 
the poor bio-distribution in vivo and scarce ability to cross 
the blood brain barrier (BBB) [22, 23].
In this study we assessed the EZH2 expression 
and role in the SLCs derived from MB belonging to the 
Sonic Hedgehog (SHH) subgroup, namely SHH MB-
SLCs [11]. Having established the key function of EZH2 
in this cellular context, we tested a simplified analog of 
EPZ005687 and GSK2816126 prepared by us, the N-
((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-
methyl-1-phenyl-1H-pyrazole-4-carboxamide MC3629, 
to determine its ability to target EZH2 and to impair SHH 
MB-SLCs in vitro and in vivo.
We show that either genetic or pharmacologic 
inhibition of EZH2 suppresses MB-SLCs, and in detail 
that MC3629 is able to impair MB proliferation/growth 
including its SLC compartment.
RESULTS
Genetic inhibition of EZH2 impairs SHH MB 
cells proliferation and self-renewal
We first assessed EZH2 protein levels in a series of 
MB cellular models including SHH MB-SLCs from both 
mouse models (Ptc1-/+ mice) (mMB SLCs1-3) and human 
primary tumors (hMB SLCs4-6) that we had previously 
characterized [24].
We found high expression of EZH2 in both mouse 
and human MB-SLCs that grow as oncospheres in stem 
cell-medium (SM) and lower levels in cells grown in 
FBS-supplemented medium (DFM) (Figure 1A, left). In 
these conditions, MB-SLCs acquired a “differentiated” 
phenotype with adherent morphology, expressing both 
neuronal and glial lineage markers (βIII-tubulin and 
GFAP, respectively) and reducing the expression of 
the stemness marker NANOG (Figure 1A). We also 
evaluated EZH2 levels in MB DAOY cells [25]. DAOY 
cells cultured for three days in SM, DAOY-SLCs, 
exhibited higher protein levels of EZH2 and NANOG, 
whereas they exhibited lower levels of βIII-tubulin 
and GFAP, when compared to DFM DAOY culture 
(Figure 1A).
First we tested three different lentiviral-mediated 
short hairpin silencing for EZH2 in both mouse and 
human MB-SLCs (Supplementary Figure 1A-1B), and 
then we used the most effective ones (a and d clones, 
respectively) for further experiments in the three cellular 
models described above. ShEZH2-transduced DAOY 
cells showed decreased levels of H3K27me3 together 
with impairment of cell proliferation (Figure 1B, 1C 
and 1E). Moreover, in shEZH2-transduced MB-SLCs 
we observed reduced self-renewal capacity (Figure 1D 
and 1F).
To further validate our results, we sorted hMB-
SLCs for the CD133 stemness marker (Supplementary 
Figure 1C) [24] obtaining positive (CD133+) and negative 
(CD133-) hMB-SLCs fractions, that were transduced 
using lentiviral shEZH2. ShEZH2 impaired cell viability 
in CD133+ hMB-SLCs more significantly than in CD133- 
hMB-SLCs (Supplementary Figure 1D).
Our results show that EZH2 plays a critical role in 
the maintenance of MB cells including SLCs.
Pharmacologic inhibition of EZH2 with a 
pyrazole-based EZH2 inhibitor impairs SHH 
MB-SLCs cell viability
EZH2 is a druggable target in different cancers [6], 
and commercial catalytic EZH2i, such as EPZ005687 
and GSK2816126 (Figure 2A), are used in lymphoma 
with EZH2-activating mutations and also in solid tumors 
[20, 21, 26]. Nevertheless, there are reports regarding 
limitation to EZH2i use in vivo due to poor bio-distribution 
and scarce ability to cross the BBB [22, 23].
Following our researches on design, synthesis and 
biological evaluation of histone lysine methyltransferase 
inhibitors [27–32], we developed the pyrazole-based small 
molecule MC3629 as a simplified analog of EPZ005687 
and GSK2816126. To design MC3629, we modified the 
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Figure 1: Genetic EZH2 knockdown impairs MB cell proliferation and self-renewal. (A) Left: representative Western Blot 
for EZH2 and NANOG protein levels in mMB-SLCs, hMB-SLCs and DAOY cells grown in SM and DFM. ACTIN was used as loading 
control. Right: mRNA levels of βIII-tubulin and GFAP of all the three models in SM and DFM. *p<0.05. (B-C-E) Left: representative 
Western Blot showing protein levels of EZH2, H3K27me3 and PCNA before and after shEZH2 in DAOY cells (B), mMB-SLCs (C) and 
hMB-SLCs (E). Dashed bars represent shRNA-non-target control (shCTRL). H3: loading control. Right: densitometric analysis of protein 
levels from three independent experiments. *p<0.05. (D-F) Self-renewal ability (percentage of tumorspheres) of mMB-SLCs and hMB-
SLCs after shEZH2 or shCTRL. *p<0.05.
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Figure 2: The EZH2 inhibitor MC3629 impairs SHH MB-SLCs viability. (A) Design of MC3629 starting from modification 
of the EPZ005687 and GSK2816126 structures. (B) EZH2/PRC2 assay in 10-dose IC50 mode with 2-fold serial dilution starting from 400 
μM solution. Histone H3/H4 tetramer was used as the substrate. (C) Representative Western Blot (up) and densitometric analysis (down) 
of H3K27me3 protein levels in mMB SLCs treated for 48 h with 0.5, 5 and 25 μM of MC3629. *p<0.05, **p<0.01. (D-E) Evaluation of 
cell viability, measured with MTS assay, of mMB-SLCs (D) and hMB-SLCs (E) treated with increasing concentrations of MC3629 and 
GSK2816126 at 48 h. p value versus untreated cells: *p<0.05, **p<0.01.
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structure of these two known EZH2i removing the benzene 
ring from the indazole or indole nucleus, respectively, to 
obtain a monocyclic nitrogen-containing heteroaromatic 
ring (the pyrazole ring) linked through a carboxamide 
function to the 3-aminomethyl-4,6-dimethyl-2-pyrimidone 
moiety, known to be crucial for EZH2 inhibition (Figure 
2A) [33]. The synthesis of MC3629, as well as its 
physical and chemical data, are reported in Supplementary 
Materials – Chemistry.
MC3629 was tested in the cell free enzymatic 
assay (EZH2/PRC2) in 10-dose IC50 mode with 2-fold 
serial dilution starting from 400 μM solution, using 
various histone substrates (histone H3/H4 octamer, 
histone H3/H4 tetramer, histone H3, and core histone) 
and SAM as the co-substrate. In these assays, MC3629 
displayed IC50 values in the range 5.27-15.4 μM, 
with GSK2816126 used as a reference drug (IC50 = 
9.13 nM (core histone substrate), according to the 
literature) [22] (Figure 2B, and Supplementary Figure 
2). SAM competition experiments using histone H3/
H4 octamer as the substrate confirmed its SAM-
dependent mechanism of inhibition (Supplementary 
Figure 3). The percentages of inhibition by MC3629, 
used at 200 μM, towards a panel of methyltransferases 
including lysine (EZH1 complex, DOT1L, G9a, MLL1 
complex, SET7/9), arginine (PRMT1) and DNA 
(DNMT1) methyltransferases definitively showed that 
the inhibition activity of MC3629 is selective for EZH2/
PRC2 (Supplementary Table 1).
Afterwards, we tested the ability of MC3629 (at 0.5, 
5, and 25 μM) to inhibit the EZH2 enzymatic activity on 
a cell-based assay in vitro. The lower significant MC3629 
dosage to decrease the H3K27me3 level in MB-SLCs was 
5 μM (Figure 2C).
Next, we assessed the biological effects of 
MC3629 on MB-SLCs by dose- and time-dependent 
experiments, using GSK2816126 as a reference drug. In 
both cell lines, we determined the lowest useful dose of 
MC3629 (5 μM) and the minimum effective time (48 h) 
(Figure 2D, 2E and Supplementary Figure 4A and 4B for 
data at 24 and 72 h). We next evaluated the performance 
of MC3629 on MB-SLCs in terms of cell viability in 
regards to other EZH2i in use, confirming the dose 
selection (Supplementary Figure 4C).
To test the specificity of the pyrazole-based EZH2 
inhibitor we combined the genetic and pharmacological 
inhibition of EZH2 on hMB-SLCs evaluating the 
corresponding cell viability (Supplementary Figure 5A). 
In our MB-SLC the combination of MC3629 (5 μM) with 
shEZH2 did not display any additive effect in respect to 
the shEZH2 treatment alone.
To rule out nonspecific toxic effects by MC3629, we 
tested the EZH2i on neural stem cells (NSC) as a model 
of non-transformed cells [24], and we did not observe 
any effects on H3K27me3 and PCNA protein levels 
(Supplementary Figure 5B).
Pharmacological inhibition of EZH2 impairs 
SHH MB cells proliferation and self-renewal, 
and induces apoptosis
We analyzed the biological effects of MC3629 
treatment in mMB-SLCs and hMB-SLCs using 
GSK2816126 as a reference drug. As shown in 
Figure 3A and 3B, both EZH2i significantly impaired 
H3K27me3 and PCNA protein levels, and MC3629 
induced apoptosis, detected as increased level of cleaved 
caspase 3. Furthermore, we investigated whether the two 
compounds were able to impair stemness, both MC3629 
and GSK2816126 significantly reduced mMB-SLC and 
hMB-SLC self-renewal (Figure 3C and 3D).
We then tested the effects of MC3629 and 
GSK2816126 in DAOY and DAOY-SLCs. In DAOY 
cells, H3K27me3 and PCNA levels resulted impaired only 
by MC3629 (Figure 4A). In DAOY-SLCs, H3K27me3 
and PCNA levels were down modulated by both drugs 
(Figure 4A). Such effects were confirmed in DAOY cells 
and DAOY-SLCs: MC3629 impaired cell viability in both 
cell systems after 48 h, while GSK2816126 was able to 
significantly impair DAOY-SLCs viability after 72 h of 
treatment (Figure 4B). Moreover, MC3629 induced cell 
death in DAOY-SLCs (Figure 4C).
Altogether, our results show that EZH2 
pharmacological inhibition is able to impair MB cells 
proliferation and stemness, and induce apoptosis.
MC3629 impairs SHH MB-SLCs growth and 
stemness in vivo
First, we tested both MC3629 and GSK2816126 
in the parallel artificial membrane permeability assay 
for the BBB (PAMPA-BBB), to measure the effective 
permeability (Pe, cm/s) of MC3629 through a porcine 
brain lipid (PBL) extract impregnated on a solid filter 
support, used as an artificial lipid membrane [34]. 
Propranolol and furosemide were used as positive 
and negative controls, respectively. In this assay, 
MC3629 displayed a closer capability to permeate the 
lipid membrane to propranolol than GSK2816126, as 
highlighted by the Δ values (Table 1 and Supplementary 
Figure 6).
Dose finding experiments showed that twice/week 
intra-peritoneal injection of MC3629 at 20 μMol/Kg led 
to a significant reduction of H3K27me3 levels in the 
cerebella of 6-day-old mice (Supplementary Figure 7A). 
At this dose, we observed reduced levels of H3K27me3 
not only in cerebellum but also in brain (Figure 5A), 
indicating that MC3629 crosses the BBB.
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Figure 3: Biological effects of EZH2 inhibition in SHH MB-SLCs. (A-B) mMB-SLCs and hMB-SLCs were treated for 48 h with 
5 μM of MC3629 or GSK2816126. Representative images of Western Blot (left) and densitometric analysis (right) of H3K27me3, PCNA, 
and cleaved caspase 3 (cleaved CSP-3). H3: loading control. Dashed bars represent DMSO-treated cells (CTRL). *p<0.05, **p<0.01. (C-D) 
Self-renewal measured by clonogenic assay. *p<0.05, **p<0.01.
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Figure 4: Biological effects of EZH2 inhibition in DAOY cells and DAOY-SLCs. (A) DAOY cells and DAOY-SLCs were 
treated for 48 h with 5 μM of MC3629 or GSK2816126. Representative images of Western Blot (left) and densitometric analysis (right) of 
H3K27me3 and PCNA. H3: loading control. Dashed bars represent DMSO-treated cells (CTRL). *p<0.05. (B) Evaluation of cell viability, 
measured with MTS assay, of DAOY and DAOY-SLCs treated for 48 h and 72 h with 5 μM of MC3629 or GSK2816126. *p<0.05. (C) 
Percentage of cell death assessed in DAOY and in DAOY-SLCs treated with both compounds for 72 h. Bars represent the mean of at least 
three independent experiments performed in triplicate mean±S.D. *p<0.05.
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Next, we generated xenograft DAOY-SLCs 
orthotopic tumors (XT-MB) in nude mice that grew as 
tumor masses with the characteristics of MBs.
Mice treatment with MC3629 significantly 
impaired XT-MB growth (Figure 5B), and Western Blot 
analysis of tumor xenografts revealed a reduction of 
H3K27me3 in treated mice (Figure 5C). Interestingly, 
tumors from treated mice also showed significantly 
lower levels of NANOG protein (Figure 5C), and a 
significant reduction of proliferating Ki67-positive cells 
as well (Figure 5D).
Finally, we observed induction of apoptosis, 
detected as increased level of cleaved caspase 3 in treated 
mice (Supplementary Figure 7B).
Taken together, these data show that MC3629 is 
effective in hampering MB-SLCs growth in vivo.
DISCUSSION
Epigenetic alterations have been shown to be 
important in cancer initiation and progression [12, 13, 
35]. Among these, histone H3K9 and H3K27 methylation 
play a key role in cancer due to their association with gene 
silencing [36–39].
Based on the EZH2 role in tumorigenesis and stem 
cell maintenance, studies have been focused on targeting 
EZH2, a H3K27 methyltransferase, as a novel cancer 
treatment, and aimed to identify small molecules that 
inhibit its catalytic activity [5, 6, 40–42].
Recently, several groups reported compounds (e.g. 
GSK2816126, EPZ005687, EPZ6438, El1, UNC1999 
and the second generation drug tazemetostat) that directly 
and selectively inhibit the EZH2/PRC2 enzymatic 
activity [17, 42, 43]. Among them, GSK2816126 is 
characterized by high and selective biochemical and 
cellular on-target potency, assessed by decrease in H3K27 
trimethylation levels, has been validated in preclinical 
studies for treatment of lymphoma with EZH2-activating 
mutations [21], and is actually in phase I clinical trial for 
the treatment of lymphomas, solid tumors and multiple 
myeloma (https://clinicaltrials.gov/ct2/results?term=GSK
2816126&Search=Search).
In MB cells, pharmacological inhibition of EZH2 
was achieved by the use of DZNep, an inhibitor of SAH 
hydrolase that inhibits EZH2 through an indirect way 
[12]. Nevertheless, this compound displays poor EZH2 
selective inhibition [44] and is not in clinical use due to 
its toxicity [19].
With this study, we tested the biological activity 
of the catalytic EZH2 inhibitor MC3629, designed and 
prepared by us as a simplified analog of EPZ005687 and 
GSK2816126, in the SHH MB cancers cells and SLCs.
In MB-SLCs derived in our laboratory from patients 
affected by SHH MB or from SHH MB murine model, the 
genetic silencing of EZH2 led to reduction of H3K27me3 
levels, reduction of proliferation, and self-renewal 
impairment.
In the same cellular models, we tested MC3629 
using GSK2816126 as a reference drug. MC3629 at 5 
μM displayed significant biological activity impairing 
cell proliferation and self-renewal, and inducing 
apoptosis. When co-administered with shEZH2 to hMB-
SLCs, MC3629 did not show any additive effect on 
cell viability, thus confirming its selective action on the 
methyltransferase target.
Prompted by our results, we tested MC3629 in 
PAMPA-BBB assay to ascertain its capability to cross BBB 
in vitro. Moreover, we observed the ability of MC3629 to 
reduce H3K27me3 levels in brain and cerebellum in vivo. 
Finally, we treated MB xenografted mice with MC3629, 
to extend its biological activity in vivo. By this set of 
experiments, we observed a significant decrease of tumor 
volume, a reduction of stemness and cell proliferation, and 
induction of apoptosis in treated mice.
Overall, in this study we validated EZH2 as an 
attractive target for SHH MB cancer and cancer stem 
cell impairment, and showed that EZH2 pharmacological 
inhibition exerted by MC3629 is effective in MB cells and 
in MB xenografted mouse models.
Table 1: Log Pe values of tested compounds in the PAMPA-BBB
COMPOUND Log Pe Δ *
GSK2816126 -5.41 ± 0.04 -0.20
MC3629 -5.33 ± 0.01 -0.12
propranolol (positive control) -5.21 ± 0.06
furosemide (negative control) under detection limit
*Respect to propranolol.
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Figure 5: Biological effects of MC3629 in vivo. (A) Representative Western Blots show H3K27me3 levels in cerebellum and brain 
from wild type mice treated with MC3629 or vehicle (CTRL). Dot plots represent densitometric analysis of all samples. *p<0.05. (B-D) 
Xenograft tumors (XT-MB) were generated in mice, after 10 days MC3629 was administered twice a week for 3 weeks; control mice were 
treated with vehicle (CTRL). (B) Xenograft volume (mm3) evaluated at the maximum diameter; dot plot represents mean±S.D. *p<0.05. 
(C) Representative images of Western Blot and densitometric analysis of H3K27me3 and NANOG. H3: loading control *p<0.05. (D) 
Xenograft sections were immunostained for the proliferation marker Ki67: on the left, dot plot shows Ki67 levels of proliferating cells; on 
the right, representative images of the staining. *p<0.05.
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MATERIALS AND METHODS
Drug synthesis
The synthetic procedure to prepare MC3629 as well 
as its physical, chemical and spectral data are reported in 
Supplementary Materials – Chemistry.
EZH2 assay
Reagents: Reaction buffer; 50 mM Tris-HCl 
(pH 8.0), 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 
mM PMSF, 1% DMSO. Reaction Conditions: EZH2: 
Complex of human EZH2 (GenBank Accession No. 
NM_004456), (amino acids 2-end) with N-terminal His 
tag, MW= 86 kDa, human EED (NM_003797) (a-a 2-end) 
with N-terminal Flag tag, MW= 51 kDa, human SUZ12 
(NM_015355) (a-a 2-end) with N-terminal His tag, MW 
= 87 kDa, Human AEBP2 (NM_153207) (a-a 2-end) with 
N-terminal His tag, MW= 53 kDa, and human RbAp48 
(NM_005610) (a-a 2-end) with N-terminal His tag, MW 
= 48 kDa, co-expressed in baculovirus expression system. 
Substrate: 5 μM histone H3/H4 tetramer. Methyl donor: 
1 μM S-adenosyl-L-[methyl-3H]methionine (3H-SAM). 
Enzyme: 100 nM EZH2 complex. Reaction Procedure: 
the indicated substrate was dissolved in freshly prepared 
Reaction Buffer; EZH2 was delivered into the substrate 
solution and mixed gently. The compound was dissolved 
in DMSO to a stock of 20 mM and was tested in a 10-dose 
IC50 mode with 2-fold serial dilution starting at 400 μM. 
The compound was delivered in DMSO into the EZH2 
reaction mixture by using Acoustic Technology (Echo 
550, LabCyte Inc. Sunnyvale, CA) in nanoliter range, 
and incubated for 15 min; 3H-SAM was delivered into 
the reaction mixture to initiate the reaction; the reaction 
mixture was incubated for 1 h at 30 °C and then delivered 
to filter-paper for detection; data were analyzed using 
Excel and GraphPad Prism 5 software for IC50 curve fits. 
For SAM competition experiments, the same procedure 
was used with different SAM concentration (1, 2.5. 5, and 
10 μM) and H3/H4 octamer as the substrate.
EZH1 complex, DOT1L, G9a, MLL1 complex, 
SET7/9, PRMT1, and DNMT1 assays
The appropriate methyltransferase (MT) substrate 
(0.05 mg/ml core histone for EZH1 complex, 0.05 mg/
ml oligonucleosomes for DOT1L, 5 μM histone H3 (1-
21) peptide for G9a, 0.05 mg/ml nucleosomes for MLL1 
complex, 0.05 mg/ml core histone for SET7/9, 5 μM 
histone H4 for PRMT1, and 0.001 mg/ml poly(dI-dC) for 
DNMT1) was added in freshly prepared Reaction Buffer 
(50 mM Tris-HCl (pH 8.5), 5 mM MgCl2, 50 mM NaCl, 
0.01% Brij35, 1 mM DTT, 1% DMSO). The MT enzyme 
was delivered into the substrate solution and the mixture 
was mixed gently. Afterwards, the tested compound 
dissolved in DMSO was delivered into the enzyme/
substrate reaction mixture by using Acoustic Technology 
(Echo 550, LabCyte Inc. Sunnyvale, CA) in nanoliter 
range, and 1 μM 3H-SAM was also added into the reaction 
mixture to initiate the reaction. The reaction mixture was 
incubated for 1 h at 30 °C and then it was delivered to 
filter-paper for detection. The data were analyzed using 
Excel and GraphPad Prism software for IC50 curve fits (for 
EZH1 complex).
Cell culture
DAOY cells were obtained from ATCC and cultured 
in MEM medium (Gibco, Invitrogen), supplemented with 
10% heat-inactivated fetal bovine serum, 1% sodium 
pyruvate, 1% non-essential amino acid solution, 1% 
L-glutamine and penicillin/streptomycin. Human and 
mouse stem-like cells (hMB-SLC and mMB-SLC) were 
derived, as previously described from primary human 
SHH-MBs and from spontaneous tumors arisen in Ptc+/-  
mice [24]. DAOY-SLCs were obtained as described in 
Alimova et al., 2012 [12].
All SLCs were maintained in DMEM/F12 
supplemented with 0.6% glucose, 25 mg/ml insulin, 60 
mg/ml N-acetyl-L-cystein, 2 mg/ml heparin, 20 ng/ml 
EGF, 20 ng/ml bFGF (Peprotech, Rocky Hill, NJ), 1X 
penicillin-streptomycin and B27 supplement without 
vitamin A (Gibco).
For differentiation experiments, hMB-SLCs and 
mMB-SLC were mechanically dissociated and plated 
for 48 h on D-poly-lysine coated dishes in differentiation 
medium (DMEM/F12 with N2 supplement and 2 mg/ml 
heparin, 0,6% glucose, 60 mg/ml N-acetyl-L-cysteine, 1% 
FBS).
For self-renewal assessment, clonogenic assay 
was performed as previously described [24]. Briefly: 
oncospheres were disaggregated with non-enzymatic 
cell dissociation buffer (Sigma) and cells were plated at 
clonal density (1-2 cells/mm2) into 96-well plates and 
cultured for an appropriate number of days (7-15) until 
oncospheres were countable.
Infection, treatments and cell viability assay
For lentiviral-transduction of specific anti-
EZH2, short hairpins lentiviral particles were 
purchased from Sigma: MISSION shRNA-non-target 
control Transduction Particles (SCH002V); three 
human Lenti ShEZH2: MISSION shRNA EZH2 
Lentiviral (SHCLNV) Clones TRCN0000010475, 
TRCN0000040074 and TRCN0000040077; three murine 
Lenti ShEZH2: MISSION shRNA EZH2 Lentiviral 
Clones TRCN0000304505, TRCN0000039041 and 
TRCN0000039042. Clone TRCN0000010475 for human 
and Clone TRCN0000304505 for mouse were used for the 
experiments since they demonstrated the best knock-down 
efficency with less off-target; cells were infected for 48 h.
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Unless otherwise specified, cells were treated for 48 
h with either GSK2816126 (Selleckchem) or MC3629 at 5 
μM. To evaluate cell viability cells were plated at a density 
of 5×103 cells/well in 96-well plates and were incubated 
with MTS solution (CellTiter 96® AQueous One Solution 
Promega).
Fluorescence-activated cell sorting
Cells were sorted based on CD133 expression levels 
using a FACSAriaIII (BD Biosciences) equipped with a 
633 nm laser and FACSDiva software (BD Biosciences 
version 6.1.3). Briefly, cells were immunostained with 
APC-conjugated anti-CD133 (Miltenyi Biotec) according 
to manufacturer’s protocol, and were then subjected to cell 
sorting. Cells were gated using forward and side scatter 
(FSC-A and SSC-A) plot to identify live cells (average 
65%), and were then detected in the APC channel for 
CD133 expression. Following this gate strategy, cells were 
sorted for expression of CD133 (APC- and APC+ cells) 
and subsequently checked for purity.
Trypan blue test
Trypan blue exclusion test was used to count viable 
or death cells present in a cell suspension [45]. Each 
sample was measured in triplicate and repeated at least 
three times.
Western blot
Western blots were performed according to standard 
procedures [46]. Briefly, protein lysates were prepared 
using RIPA buffer with fresh protease inhibitors. Lysates 
were separated on SDS polyacrylamide gels. Proteins 
were transferred on nitrocellulose membrane (0.45 
micron) (PerkinElmer). Membranes were blocked for 1 h 
at room temperature in 5% nonfat dry milk and incubated 
overnight at 4 °C with antibodies against EZH2 (4905S 
Cell signaling), H3K27me3 (07-449 Millipore), PCNA 
(2586 Cell signaling), ACTIN (I-19 sc-1616; Santa Cruz 
Biotechnology), GAPDH (ab9484, Abcam), cleaved 
CSP-3 (D-175 9661S; Cell Signaling) and H3 (ab1971, 
Abcam). HRP-conjugated secondary antibodies (Santa 
Cruz Biotechnology) were used in combination with 
enhanced chemiluminescence (ECL Amersham).
RNA extraction and quantitative real-time PCR
RNA was isolated from cells using TriReagent 
(Ambion) and retro transcribed using the High Capacity 
cDNA Reverse Transcription kit (Thermo Scientific). 
cDNAs were analyzed using the ViiA™ 7 Real-Time 
PCR System (Thermo Scientific) SensiFAST™ Probe Lo-
ROX (Bioline), and TaqMan gene expression assays for 
βIIITubulin (Hs-00801390_s1, Mm00727586_s1) and 
GFAP (Hs-00909233_m1, Mm01253033_m1) for human 
and mouse respectively. Results were evaluated using the 
2-ΔΔCT method and mRNA quantification was normalized 
to 2 endogenous controls: ACTIN and GAPDH.
PAMPA-BBB
Donor solution (500 μM or 250 μM) was prepared 
by diluting 10 or 5 mM DMSO compound stock solution 
using phosphate buffer (pH 7.4, 0.01 M). Filter membrane 
was coated with 5 μl of BBB-specific lipid solution 
prepared dissolving 16 mg of PBL (Avanti Lipids Polar, 
141101P) in 600 μl of n-dodecane. Donor solution (150 
μl) was added to each well of the filter plate. To each well 
of the acceptor plate 300 μl of solution (5% DMSO in 
phosphate buffer) were added. Each compound was tested 
in triplicate. The sandwich was incubated for 24 h at room 
temperature under gentle shaking. After the incubation 
time, the sandwich plates were separated and 250 μl of the 
acceptor plate were transferred to a UV quartz microtiter 
plate and measured by UV spectroscopy, using a Multiskan 
GO microplate spectrophotometer (Thermo Scientific) at 
250−500 nm at step of 5 nm. Reference solutions (250 μl) 
were prepared diluting the sample stock solutions to the 
same concentration as that with no membrane barrier. The 
BBB permeability value Log Pe is determined applying 
the equation:
log logP C ln
drug
druge
acceptor
equilibrium
= ⋅ − −
[ ]
[ ]










 1













,
where C V V
V V area time
D A
D A
=
⋅
+( ) ⋅






In this equation, VA is the volume of the acceptor 
compartment (0.3 cm3), VD is the donor volume (0.15 
cm3), area is the accessible filter area (0.24 cm2), and time 
is the incubation time in seconds.
Mice experiments
Mice were purchased from Charles River Laboratories 
and maintained in the Animal Facility at Sapienza 
University of Rome. All procedures were performed in 
accordance with the Guidelines for Animal Care and Use 
of the National Institutes of Health with the approval of 
the Ethics Committee for Animal Experimentation (Prot. N 
03/2013) of Sapienza University of Rome.
In vivo treatment
CD1 wild-type mice were treated intra-peritoneally 
with 20 μMoles/Kg of MC3629 (n=8 for each group). 
Treatment was performed at the age of 8 and 10 days post 
natal and mice were sacrificed at 12 days post natal. Brain 
and cerebellum tissues were collected for analysis.
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Medulloblastoma xenografts
DAOY-SLCs were stereotaxically implanted into 
the cerebellum of nude mice by using the following 
coordinates according to the atlas of Franklin and Paxinos: 
6.6 mm posterior to the bregma; 1 mm lateral to the 
midline; and 2 mm ventral from the surface of skull of 
mice, under ketamine (100 mg/kg, i.p.)/xylazine (10 mg/
kg, i.p.) anesthesia. Cells (2x105 per 3 μl) were implanted 
at an infusion rate of 1 μl/min. Mice were separated 
into two groups. Group 1 (n=8) was intraperitoneally 
treated with MC3629 (20 μMoles/Kg) suspended in 10% 
(2-Hydroxypropyl)-β-cyclodextrin +1%DMSO (Sigma), 
Group 2 (n=8) was treated with 10% (2-Hydroxypropyl)-
β-cyclodextrin +1%DMSO (Sigma). After 21 days of 
treatment, animals were sacrificed and brains were 
formalin fixed and paraffin embedded. Brain tumor 
volume calculation: Serial thick coronal sections (2 μm) 
starting from mesencephalon to the end of cerebellum 
were performed. The analysis was performed on 20 
sections, sampled every 40 μm on the horizontal plan of 
the cerebellum, in which the tumor was identified and 
outlined at 2.5X magnification.
Every 40 μm of brain slice, hematoxylin and eosin 
(H&E) staining was performed. Tumor area of every 
slice was evaluated with a microscope (Axio Imager M1 
microscope) equipped with a motorized stage and software 
Image Pro Plus 6.2. The following formula was used to 
calculate brain tumor volume: tumor volume = sum of 
(measured area for each slice x slice thickness x sampling 
frequency) [47].
Immunohistochemistry
Paraffin-embedded sections were deparaffinized, 
and stained with either H&E or immunohistochemical 
stains as specified. Heat-induced epitope retrieval was 
performed with citrate buffer pH 6. Sections were 
incubated with ki67 primary antibody (Thermo Scientific) 
for 1 h. Ki67 expression was expressed as percentages of 
total cells with labeled nuclei.
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